Research Reference
Calcitonin
FDA-approved peptide hormone for hypercalcemia and osteoporosis
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Calcitonin is an FDA-approved peptide hormone used to treat hypercalcemia and postmenopausal osteoporosis.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 0.2 mg vial. Resulting concentration: 0.1 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 100 mcg | 100 units | 1 mL | SubQ, dailyFDA-approved (hypercalcemia) |
| 200 mcg | 200 units | 2 mL | SubQ, dailyHigher hypercalcemia dose |
| 100 mcg | 100 units | 1 mL | SubQ, daily (osteoporosis)FDA-approved (postmenopausal osteoporosis) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
FDA-approved calcitonin is supplied as a pre-mixed solution for injection (salmon calcitonin, 200 IU/mL) or as a nasal spray; the injectable form requires no reconstitution. Compounded research-peptide forms, when referenced, are supplied as a lyophilized powder in microgram-range vials.
For a 0.2 mg (200 mcg) vial reconstituted with 2 mL of bacteriostatic water, the resulting concentration is 0.1 mg/mL (100 mcg/mL); a 100 mcg dose draws to 10 units (0.1 mL) on a U-100 insulin syringe. For a 0.5 mg (500 mcg) vial reconstituted with 2.5 mL, the concentration is 0.2 mg/mL (200 mcg/mL); a 100 mcg dose draws to 5 units (0.05 mL). Gently swirl — do not shake — to mix. Store reconstituted vials refrigerated at 2–8°C.
Cycling Protocol
The FDA-approved osteoporosis protocol describes daily administration (100 IU subcutaneously/intramuscularly, or 200 IU intranasally) for the duration of treatment, with periodic reassessment of bone mineral density and fracture risk. Treatment is typically continued as long as benefit is demonstrated.
For acute hypercalcemia, calcitonin is used for several days to rapidly lower serum calcium, often followed by or combined with bisphosphonates for longer-term control. No standard on/off cycle is described; duration is dictated by clinical response.
Routes of Administration
Subcutaneous injection (FDA-approved): Commonly administered into the abdomen, thigh, or arm for hypercalcemia and osteoporosis.
Calcitonin is not administered orally due to peptide degradation.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Acute Hypercalcemia | Calcitonin + IV bisphosphonate (zoledronate) | Rapid (calcitonin) + sustained (bisphosphonate) calcium lowering | | Osteoporosis | Calcitonin + calcium + vitamin D | Standard bone-health support |
Calcitonin is FDA-approved; compounded research-peptide forms are not FDA-approved and are sold for research purposes only. Stacking with antiresorptive agents is described in the clinical literature under medical supervision.
Side Effects & Safety
- Flushing of the face and hands — very common, particularly with injectable forms
- Nausea and vomiting — common, dose-related
- Injection-site reactions — redness or mild pain at the injection site
- Nasal irritation or rhinitis — with the intranasal form
- Tingling or warmth — transient, often with the first doses
- Hypersensitivity reactions — rare; the label notes the possibility of allergy, particularly to salmon-derived calcitonin
- Possible malignancy risk — a small increased incidence of malignancy was observed in some meta-analyses, leading regulatory authorities to restrict long-term use; calcitonin is generally reserved for cases where alternatives are unsuitable
Calcitonin is FDA-approved; compounded research-peptide forms are not FDA-approved.
Research Basis
Calcitonin is a 32-amino-acid peptide hormone produced by the parafollicular C cells of the thyroid gland in humans; pharmaceutical calcitonin is typically salmon calcitonin, which is more potent than the human form.
Mechanism: Calcitonin lowers serum calcium by inhibiting osteoclast-mediated bone resorption and increasing renal calcium excretion.
FDA approval: Approved for the treatment of hypercalcemia of malignancy and Paget disease of bone, and (intranasal and injectable forms) for postmenopausal osteoporosis in women who cannot or will not use other therapies.
Limitations: Efficacy for fracture reduction is modest compared to bisphosphonates and other antiresorptives, and long-term use has been restricted in some jurisdictions due to a signal for increased malignancy risk in meta-analyses. It is generally reserved for specific indications or short-term use.